Rx Sampling In "Spotlight" Of Boston Grand Jury As Part Of TAP Investigation
Executive Summary
Pharmaceutical companies should consider how their sampling programs will look in "the very bright spotlight of a federal grand jury investigation," Boston Assistant U.S. Attorney Michael Loucks said during the Food & Drug Law Institute annual meeting April 19 in Washington, D.C.
You may also be interested in...
PBM Subpoenas Piling Up; AdvancePCS Notes Firms Are Good Source Of Data
The Boston U.S. Attorney's Office subpoenas to pharmacy benefit managers reflect the position of PBMs as the best source of data on pharmaceutical use and pricing, AdvancePCS said
PBM Subpoenas Piling Up; AdvancePCS Notes Firms Are Good Source Of Data
The Boston U.S. Attorney's Office subpoenas to pharmacy benefit managers reflect the position of PBMs as the best source of data on pharmaceutical use and pricing, AdvancePCS said
AstraZeneca Zoladex Marketing Practices Under Investigation By DoJ
A Department of Justice investigation into AstraZeneca's Zoladex marketing practices is continuing following the recent settlement with TAP over Lupron.